BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

United Therapeutics Corporation (UTHR) Repurchases 766,666 Shares Of Its Common Stock From Toray Industries, Inc. (TRYIY)


7/28/2006 10:30:06 AM

SILVER SPRING, Md., July 27 /PRNewswire-FirstCall/ -- United Therapeutics Corporation today announced that it repurchased an aggregate of 766,666 shares of its common stock, par value $0.01 per share, from Toray Industries, Inc. ("Toray") for an aggregate cash purchase price of $42,231,030 (or $55.08 per share). The purchase price was the average of the closing prices of United Therapeutics' common stock for the 30 consecutive trading days through July 26, 2006.

"I am very pleased to be able to return value to all of our shareholders via this reduction in outstanding stock," said Martine Rothblatt, Ph.D., Chairman and CEO of United Therapeutics. "Effecting this share repurchase from Toray -- one of our most valued strategic partners -- enabled us to also accommodate their strong preference for achieving liquidity via a non-market transaction."

Under a series of agreements entered into between 1998 and 2000, United Therapeutics licensed from Toray certain exclusive rights to develop and market immediate-release and sustained-release formulations of beraprost, Toray's oral prostacyclin for the treatment of certain vascular and cardiovascular indications. Toray retains ownership of 100,000 shares of United Therapeutics common stock and, as discussed in United Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2005, upon Toray's achievement of certain clinical milestones, United Therapeutics will grant options to Toray to purchase an additional 500,000 shares of United Therapeutics' common stock at the then-current market price.

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

United Therapeutics Corporation

CONTACT: Andrew Fisher of United Therapeutics Corporation,+1-301-608-9292, or Afisher@unither.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES